Search Results
Mar 19, 2026, 10:10 ET Why Your Berberine Failed: RevGenetics Unveils the Absorption Gap Solution
in the small intestine.DiBerberine™ Proprietary Blend (500mg per capsule): This leverages the profound pharmacokinetic advantage of DHB. A 2022 study showed a 100mg dose yielded ~6.7x greater plasma exposure than 500mg of standard berberine HCl.
More news about: RevGenetics
Mar 19, 2026, 09:00 ET ImmunoBrain Presents Clinical Data for First Immune Checkpoint Therapy Approach in Alzheimer's Disease at AD/PD™ 2026
study drug and no cases of amyloid-related imaging abnormalities (ARIA). CSF biomarker analysis (Neurogranin, total-Tau, and pTau181) at a dose of 30 mg/kg of IBC-Ab002, compared to placebo, is concordant with potential synaptic and neuronal protection."There remains a significant unmet need for
More news about: ImmunoBrain Checkpoint Inc.
Mar 19, 2026, 08:02 ET Xyzal® Helps Runners Rise Ready as Official Allergy Sponsor of the 2026 Boston Marathon Presented by Bank of America
Disclaimer: BENADRYL® dosing guide: Adult & Children's Diphenhydramine Dosage. ZYRTEC®Allergy Relief Tables with 10 mg Cetirizine. CLARITIN® Tablets 24-Hour- Relieve Allergy SymptomsMedia contact: Nyaa Ferary,
More news about: Xyzal
Mar 19, 2026, 07:30 ET Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
BELIEVE study, participants dosed with bimagrumab as monotherapy, achieved reductions in total body fat mass comparable to high-dose semaglutide (2.4 mg) at one year (-25.3% vs. -24.8%, respectively). In the same study, bimagrumab-treated individuals saw a greater reduction in metabolically active visceral
More news about: Biohaven Ltd.
Mar 19, 2026, 06:45 ET Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
retatrutide initiated treatment with 2 mg once-weekly and increased the dose in a step-wise approach every four weeks until reaching the target dose of 4 mg (via one step at 2 mg), 9 mg (via steps at 2 mg, 4 mg and 6 mg) or 12 mg (via steps at 2 mg, 4 mg, 6 mg and 9 mg).The TRANSCEND-T2D Phase 3 clinical
More news about: Eli Lilly and Company
Mar 18, 2026, 11:22 ET 總生存期顯著延長：蘆康沙妥珠單抗(sac-TMT) OptiTROP-Lung03研究OS最終分析結果亮相
OptiTROP-Lung03研究旨在評估蘆康沙妥珠單抗(sac-TMT)單一療法(5 mg/kg每2週一次) 對比多西他賽，在既往接受過EGFR-TKI和含鉑化療治療的局部晚期或轉移性EGFR突變非小細胞肺癌(NSCLC)患者中的有效性和安全性。此前在2025年ASCO年會上公佈的結果顯示，在137例隨機入組的患者中，相較於多西他賽，蘆康沙妥珠單抗(sac-TMT)在無進展生存期(PFS）和總生存期(OS)方面具有顯著統計學意義和臨床意義的改善——經BICR評估的PFS風險比(HR)為0.30(95%
More news about: 科倫博泰
Mar 18, 2026, 10:27 ET Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study
The OptiTROP-Lung03 study was designed to evaluate the efficacy and safety profile of sac-TMT monotherapy (5 mg/kg every other week) versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have previously treated
More news about: Kelun-Biotech
Mar 18, 2026, 08:35 ET From Potato Roses to Bunny Boards: Easter Brunch Recipes Crafted to Impress
for Your Easter BrunchPotatoes are more than a beautiful canvas. One 5.3 oz skin-on potato delivers more potassium than a banana (620 mg vs. 450 mg) and 30% of your daily vitamin C, making them the perfect foundation for a nutritious, crowd-pleasing Easter brunch.For more Easter potato
More news about: Potatoes USA
Mar 18, 2026, 08:00 ET MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
placebo). Part 3A is designed to evaluate a one-step titration regimen with 16 mg for 4 weeks followed by 48 mg for 12 weeks, while Part 3B will evaluate a two-step titration regimen with 16 mg for 4 weeks, 32 mg for 4 weeks, and 64 mg for 8 weeks. The study will assess safety, tolerability, pharmacokinetics
More news about: MetaVia Inc.
Mar 18, 2026, 07:49 ET FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
www.icotyde.com. ICOTYDE™ INDICATION AND IMPORTANT SAFETY INFORMATIONWHAT IS ICOTYDE™ (icotrokinra)?ICOTYDE 200 mg is a prescription medicine used to treat moderate to severe plaque psoriasis in adults and children 12 years of age and older who weigh at least 88 pounds
More news about: Johnson & Johnson
Mar 18, 2026, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
100 mm³, mice were randomized into four groups: vehicle control; Quar Oze alone (25 μg/mouse, IV, every three days); alectinib alone (0.5 mg/kg for sensitive or 15 mg/kg for resistant, oral, daily); and Quar Oze plus alectinib at the same doses. In the sensitive model, tumors in the alectinib-treated group
More news about: Genprex, Inc.
Mar 18, 2026, 06:50 ET Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDTThe European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio® in adults living with Fabry disease providing a meaningful reduction in treatment burden
More news about: Protalix BioTherapeutics, Inc.
Mar 17, 2026, 16:35 ET Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption
More news about: Nuvation Bio Inc.
Mar 17, 2026, 16:30 ET Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
potency with tumor regressions in xenograft studies at low single-digit mg/kg doses, and in non-human primate studies, Whitehawk's ADCs demonstrated a high tolerability with a highest non-severely toxic dose (HNSTD) of 60 mg/kg. Underpinning these results is one of the lowest reported free payload in
More news about: Whitehawk Therapeutics, Inc.
Mar 17, 2026, 15:00 ET Chega ao Brasil eplontersena para tratamento da amiloidose hereditária mediada por transtirretina com polineuropatia (ATTRv-PN)
monitoramento clínico durante o uso, conforme destacado na bula. Eplontersena é administrado sob prescrição médica por via subcutânea, em dose mensal fixa de 45 mg, e está disponível em caneta aplicadora de uso único1,4. Avanços de opções terapêuticas para ATTRv no Brasil Com a aprovação
More news about: AstraZeneca
Mar 17, 2026, 10:13 ET NIH-Funded Randomized Clinical Trial Evaluating Weekly BRIXADI® for Opioid Use Disorder in Pregnancy and 12-months Postpartum Published in JAMA Internal Medicine
program and comply with the REMS requirements. BRIXADI (buprenorphine) extended-release injection (weekly, 50 mg/mL buprenorphine) and BRIXADI (monthly, 356 mg/mL buprenorphine) are different formulations. Doses of BRIXADI (weekly) cannot be combined to yield an equivalent monthly dose.
More news about: Braeburn
Mar 17, 2026, 09:04 ET Protect Against UV Damage & Soothe Sensitive Skin with Kiehl's
rays.Nano-Array Mineral Filter Technology: With nano zinc oxide that disperses smoothly and helps reduce the white cast that zinc oxide can have.40MG Cica Centella: Soothes skin by replenishing moisture and helps improve skin's moisture barrier.Clinically Proven Results:3
More news about: Kiehl's Since 1851
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia submissão regulatória suplementar de MINJUVI® (tafasitamabe) para linfoma folicular na Argentina e no México
eventos futuros, exceto conforme exigido por lei.Referências:MINJUVI (tafasitamab) Powder for solution for infusion 200 mg ANVISA; precribing information January, 2026. Accessed February 19th 2026.
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia la presentación regulatoria complementaria de MINJUVI® (tafasitamab) para linfoma folicular en Argentina y México
eventos futuros, excepto según lo requiera la ley.Referencias:MINJUVI (tafasitamab) Powder for solution for infusion 200 mg ANVISA; precribing information January, 2026. Accessed February 19th 2026.
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics Anuncia Aprovação de Indicação Adicional para MINJUVI® (tafasitamabe) no Brasil
eventos futuros, exceto conforme exigido por lei.Referências:MINJUVI (tafasitamab) Powder for solution for infusion 200 mg ANVISA; precribing information January, 2026. Accessed February 19th 2026.
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia la aprobación de una indicación adicional para MINJUVI® (tafasitamab) en Brasil
futuros, excepto según lo requiera la ley.Referencias:MINJUVI (tafasitamab) polvo para solución para infusión 200 mg – ANVISA; información para prescribir, enero de 2026. Consultado el 19 de febrero de 2026.Kanters S, Ball G, Kahl B, et al. Clinical outcomes
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 06:00 ET 口服小分子胰澱素受體激動劑ASC39在臨床前模型中顯示出類似eloralintide的胰澱素選擇性與療效
pM。這些數據表明，相較於hCTR，ASC39對hAMY1R具有高度選擇性，且ASC39對hAMY1R的選擇性與eloralintide相當。ASC39與eloralintide對hAMY1R的選擇性比對hCTR的分別高40倍和64倍。在一項頭對頭飲食誘導肥胖（DIO）大鼠研究中，與接受安慰劑給藥的肥胖大鼠相比，ASC39每日口服給藥顯示出具有統計學顯著性的體重下降，與eloralintide相當（見表1）。每日一次口服給藥5 mg/kg的ASC39，連續給藥6天，產生了顯著的經安慰劑校正後的體重下降6.6%。每三天一次皮下注射3 nmol/kg的eloralintide，連續6天，產生了顯著的經安慰劑校正後的體重下降5.6%，與文獻數據一致[1]。表1. ASC39每日一次口服給藥連續6天產生了具有統計學顯著性的體重下降，其療效與eloralintide的相當。
More news about: 歌禮製藥有限公司
Mar 17, 2026, 06:00 ET Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models
administration of ASC39 resulted in statistically significant weight loss which was comparable to eloralintide (Table 1). Once-daily oral administration of 5 mg/kg ASC39 for 6 consecutive days produced significant placebo adjusted weight loss of 6.6%. Once-every-three-day subcutaneous (SQ) administration of 3
More news about: Ascletis Pharma Inc.
Mar 16, 2026, 15:47 ET SmartyPants Vitamins Launches New OB-GYN Co-Developed Prenatal Capsule Designed To Support Baby's Brain and Development*
Plus Multivitamin Capsules include:480 mg choline to support fetal brain and spinal cord development*667mcg folate as methylfolate to support fetal nervous system development*50mg of DHA included as part of a thoughtfully balanced formulaIodine
More news about: SmartyPants Vitamins
Mar 16, 2026, 09:06 ET LEGACY CANNABIS BRAND ANNOUNCES NATIONWIDE PRODUCT EXPANSION
Dreamy Blueberry - 1:1:1, 100mg THC, 100mg CBG, 100mg CBN (Sleep Recover)Sleepy Watermelon - 1:2:2, 50mg THC, 100mg CBN, 100mg CBD (Blissful Sleep)Midnight Prickly Pear - 1:1:1, 100mg THC, 100mg CBN, 100mg CBD (Deep Sleep)Jamberry - 1:1, 100mg THC, 100mg CBN (Classic)The
More news about: Smokiez Edibles